Esperion Therapeutics (ESPR) - Cash on Hand per Share

Esperion Corp - graphic logo of issuer ESPR

This cash per share chart from GURU.Markets demonstrates the liquidity of Esperion Therapeutics (ESPR), where the parameter has settled at 0.61. This trend is driven by Nexletol sales and partner payments. Stability is supported by eco-standards for drug synthesis and chemical waste control. The company is currently scaling its non-statin portfolio, expanding its presence in the European and US markets.

Esperion (ESPR) - Cash per Share from 07/04/2022 to 07/25/2026

Comprehensive metric breakdowns and analytics for Esperion Corp (ESPR)

- cash availability and cash flow indicators:
General company analysis:ESPR, Esperion Therapeutics
Manufactured products of Esperion Therapeutics Inc

This indicator reflects the liquidity level per common share, allowing for the rapid tracking of capital dilution or write-downs outside of quarterly reports. By analyzing the calculated cash per share, an investor can see the resources Esperion Therapeutics (ESPR) possesses to compete with pharma behemoths for insurance quotas, where a sufficient cash reserve guarantees survival, but an excess may signal stagnation in development.